Innovation Pharmaceutical revenue grows, net loss deepens to CNY 21m

CSPC Innovation Pharmaceutical reported a 7.18% increase in revenue for the third quarter of 2025, reaching CNY 543,456,419.92. Year-to-date revenue also grew by 7.71% to CNY 1,593,014,097.66. However, the company experienced a notable decline in profitability, with a net loss attributable to shareholders of CNY -21,302,733.89 for the quarter, an over 1,000% decrease compared to the same period last year. Year-to-date, the net loss attributable to shareholders deepened by 117.26% to CNY -24,048,877.47.

The company's total assets increased by 3.13% to CNY 6,210,880,638.20 as of September 30, 2025. Operating cash flow improved significantly, reducing its net outflow by 81.67% to CNY -175,121,559.93 year-to-date. This improvement was partly due to the company addressing historical research and development payments. The company also increased its investment in biopharmaceutical R&D and market promotion, leading to higher selling and R&D expenses.

A significant event noted was the approval to acquire an additional 29% equity in its subsidiary, Joincare Bioscience, for CNY 1,100,000,000.00, increasing CSPC Innovation Pharmaceutical's stake from 51% to 80%. This strategic move aims to deepen the company's footprint in innovative biopharmaceuticals and create greater shareholder value.